Ocugen brings state lawmakers to its facility to review biotech initiatives

Ocugen brings state lawmakers to its facility to review biotech initiatives
Ocugen meets with state representatives

Ocugen announced it hosted Pennsylvania State Representatives Borowski and Friel at its facility this week, engaging directly with CEO Dr. Shankar Musunuri and the company team.

During the meeting, Ocugen shared updates on its current pipeline, ongoing projects, and discussed the potential implications of HB 2162, a legislative bill relevant to the company and the regional biotech sector. The discussions also covered perspectives on advancing innovation in biotechnology and the life sciences sector in Pennsylvania.

Earlier this year, Ocugen began evaluating RORα as a multi-pathway target for Alzheimer’s research, focusing on neuroinflammation and mitochondrial health, according to company statements. The firm also strengthened its clinical development leadership with the appointment of Beth Scott to oversee advanced retinal therapy trials, per a prior announcement. These initiatives are part of Ocugen’s broader strategy in the biotechnology sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.